Literature DB >> 3148286

A comparison of alfentanil requirements in European and Asian patients during general anaesthesia.

C Aun1, I T Houghton, K Chan, R H Carley, N P Salmon, Y M Lams, J A Thornton.   

Abstract

Alfentanil requirements were compared in thirty-six Asian and forty-three European patients during general anaesthesia with muscle relaxants. Alfentanil infusion at 5 micrograms/kg/min was started immediately after induction with thiopentone and alcuronium. The infusion rate was reduced to 0.5 microgram/kg/min after ten minutes. An incremental dose of 5 micrograms/kg/min for five minutes was given on each occasion when anaesthesia was clinically judged to be inadequate. Recovery parameters were recorded. Pharmacokinetics were also studied in five Europeans, four Chinese and four Nepalese. The dosage of alfentanil required was comparable in both Asian and European patients, but recovery was slower in the Asian patients. The elimination half-life in the Chinese and the Nepalese were both significantly shorter than that of the Europeans (P less than 0.05), but at the time of recovery of spontaneous ventilation, the mean plasma concentrations were not significantly different.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3148286     DOI: 10.1177/0310057X8801600403

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  2 in total

1.  Isolation of Mitochondria-Associated ER Membranes (MAMs), Synaptic MAMs, and Glycosphingolipid Enriched Microdomains (GEMs) from Brain Tissues and Neuronal Cells.

Authors:  Ida Annunziata; Jason Andrew Weesner; Alessandra d'Azzo
Journal:  Methods Mol Biol       Date:  2021

2.  Effect of cultural background and healthcare environment on postoperative opioid requirement.

Authors:  Alex H Konstantatos; Taidi Zhong; Eldho Paul; Sharon Tsang; Suming Tian; Minjun Liu; Yuyuan Liang; Yuanyuan Tian; Shina Qiao; William K K Wu; Matthew T V Chan
Journal:  Can J Anaesth       Date:  2018-12-10       Impact factor: 5.063

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.